the promising role of pacritinib for the treatment of patients with mf and severe thrombocytopenia
Published 1 year ago • 187 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
0:46
the role of pacritinib in managing thrombocytopenia in patients with myelofibrosis
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
1:46
the efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia
-
1:15
potential approval of pacritinib for the treatment of myelofibrosis
-
1:45
design and results of pacritinib for myelofibrosis trial (persist-1)
-
2:02
how to ace your rheumatology interview
-
3:35
epigenomics in precision oncology
-
9:16
protrombin time (pt) & activated partial tromboplastin time (aptt)|coagulation analyzer|wila djami
-
4:48
an insight into the management of cytopenias in mf
-
4:20
therapy-related all: etiology, prognosis, and treatment
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
1:27
insights into the reveal trial: the efficacy of ruxolitinib for the treatment of patients with pv
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
3:46
results of the phase iii persist-1 trial of pacritinib for myelofibrosis
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
2:00
the role of fedratinib in 2024 and beyond
-
0:42
talquetamab treatment in patients with r/r myeloma with prior exposure to t-cell-directed therapies
-
1:22
the value of add-on therapy approaches in mf